6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Myelodysplastic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
/ O
Acute B-OSE_Labeled_AE
Myeloid I-OSE_Labeled_AE
Leukemia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Pneumonitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Most O
common O
adverse O
reactions O
( O
> O
=20 O
% O
) O
in O
clinical O
trials O
were O
anemia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
( O
including O
asthenia B-OSE_Labeled_AE
) O
, O
vomiting B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
/ O
pharyngitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
/ O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
/ O
rash B-OSE_Labeled_AE
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
. O

( O
6.1 O
) O
* O
Most O
common O
laboratory O
abnormalities O
( O
> O
=25 O
% O
) O
were O
increase B-OSE_Labeled_AE
in O
creatinine I-OSE_Labeled_AE
, O
mean B-OSE_Labeled_AE
corpuscular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
, O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
, O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
, O
and O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Lynparza O
400 O
mg O
twice O
daily O
as O
monotherapy O
, O
has O
been O
studied O
in O
300 O
patients O
with O
g O
BRCA B-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
advanced I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
and O
223 O
of O
these O
patients O
had O
received O
3 O
or O
more O
prior O
lines O
of O
chemotherapy O
. O

In O
the O
223 O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
3 O
or O
more O
prior O
lines O
of O
chemotherapy O
( O
including O
137 O
patients O
in O
Study O
1 O
with O
measureable O
disease O
) O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
, O
adverse O
reactions O
led O
to O
dose O
interruption O
in O
40 O
% O
of O
patients O
, O
dose O
reduction O
in O
4 O
% O
, O
and O
discontinuation O
in O
7 O
% O
. O

There O
were O
8 O
( O
4 O
% O
) O
patients O
with O
adverse O
reactions O
leading O
to O
death B-NonOSE_AE
, O
two O
were O
attributed O
to O
acute B-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
, O
and O
one O
each O
was O
attributed O
to O
COPD B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
and O
suture O
rupture O
. O

Table O
1 O
presents O
the O
frequency O
of O
adverse O
reactions O
reported O
in O
> O
=20 O
% O
of O
223 O
patients O
( O
in O
6 O
studies O
) O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
advanced I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
had O
received O
3 O
or O
more O
prior O
lines O
of O
chemotherapy O
who O
were O
treated O
with O
Lynparza O
400 O
mg O
twice O
daily O
. O

The O
median O
exposure O
to O
Lynparza O
in O
these O
patients O
was O
158 O
days O
. O

Table O
1 O
Adverse O
Reactions O
Reported O
in O
> O
=20 O
% O
of O
Patients O
with O
gBRCA-Mutated O
Advanced O
Ovarian O
Cancer O
Receiving O
Lynparza O
3 O
or O
more O
lines O
of O
prior O
chemotherapy O
Adverse O
Reaction O
Grades O
1-4 O
N=223 O
% O
Grades O
3-4 O
N=223 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
34 O
18 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
43 O
8 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
22 O
1 O
Nausea B-OSE_Labeled_AE
64 O
3 O
Vomiting B-OSE_Labeled_AE
43 O
4 O
Diarrhea B-OSE_Labeled_AE
31 O
1 O
Dyspepsia B-OSE_Labeled_AE
25 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
66 O
8 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
26 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
/ O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
21 O
0 O
Myalgia B-OSE_Labeled_AE
22 O
0 O
Table O
2 O
presents O
the O
frequency O
of O
abnormal B-NonOSE_AE
laboratory I-NonOSE_AE
findings I-NonOSE_AE
in O
the O
223 O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
advanced I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
had O
received O
three O
or O
more O
prior O
lines O
of O
chemotherapy O
receiving O
Lynparza O
400 O
mg O
twice O
daily O
. O

Table O
2 O
Laboratory O
Abnormalities O
Reported O
in O
Patients O
with O
gBRCA-Mutated O
Advanced O
Ovarian O
Cancer O
Receiving O
Lynparza O
Laboratory O
Parameter1 O
3 O
or O
more O
lines O
of O
prior O
chemotherapy O
Grades O
1-4 O
N=223 O
% O
Grades O
3-4 O
N=223 O
% O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
( O
anemia B-OSE_Labeled_AE
) O
90 O
15 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
neutropenia B-OSE_Labeled_AE
) O
25 O
7 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
( O
thrombocytopenia B-OSE_Labeled_AE
) O
30 O
3 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
( O
lymphopenia B-OSE_Labeled_AE
) O
56 O
17 O
Mean B-OSE_Labeled_AE
corpuscular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
57 O
- O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
30 O
2 O
The O
following O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
have O
been O
identified O
in O
> O
=10 O
to O
< O
20 O
% O
of O
the O
223 O
patients O
receiving O
Lynparza O
and O
not O
included O
in O
the O
table O
: O
cough B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
. O

The O
following O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
have O
been O
identified O
in O
> O
=1 O
to O
< O
10 O
% O
of O
the O
223 O
patients O
receiving O
Lynparza O
and O
not O
included O
in O
the O
table O
: O
leukopenia B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
vulvovaginal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
/ O
eczema B-OSE_Labeled_AE
, O
pruritis B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
including O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
, O
and O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
. O

Table O
3 O
presents O
adverse O
reactions O
reported O
in O
> O
=20 O
% O
of O
patients O
from O
a O
randomized O
trial O
of O
Lynparza O
400 O
mg O
twice O
daily O
as O
maintenance O
monotherapy O
compared O
to O
placebo O
in O
patients O
with O
platinum O
sensitive O
, O
relapsed O
, O
high-grade O
serous O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
following O
treatment O
with O
2 O
or O
more O
platinum-containing O
regimens O
. O

Table O
4 O
presents O
the O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
in O
patients O
from O
this O
randomized O
trial O
. O

Of O
the O
96 O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutation I-Not_AE_Candidate
, O
53 O
received O
Lynparza O
, O
and O
43 O
received O
placebo O
. O

The O
median O
duration O
on O
treatment O
with O
Lynparza O
was O
11.1 O
months O
for O
patients O
with O
a O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
mutation I-Not_AE_Candidate
compared O
to O
4.4 O
months O
for O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
mutation I-Not_AE_Candidate
on O
placebo O
. O

Adverse O
reactions O
led O
to O
dose O
interruptions O
in O
26 O
% O
of O
those O
receiving O
Lynparza O
and O
7 O
% O
of O
those O
receiving O
placebo O
; O
dose O
reductions O
in O
15 O
% O
of O
Lynparza O
and O
5 O
% O
of O
placebo O
patients O
; O
and O
discontinuation O
in O
9 O
% O
of O
Lynparza O
and O
0 O
% O
in O
placebo O
patients O
. O

One O
( O
2 O
% O
) O
patient O
on O
Lynparza O
died B-NonOSE_AE
as O
a O
result O
of O
an O
adverse O
reaction O
. O

Table O
3 O
Adverse O
Reactions O
Reported O
in O
> O
=20 O
% O
of O
Patients O
with O
gBRCA-Mutated O
Ovarian O
Cancer O
in O
the O
Randomized O
Trial O
Adverse O
Reactions O
Lynparza O
N=53 O
Placebo O
N=43 O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
25 O
4 O
7 O
2 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
47 O
0 O
58 O
2 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
25 O
0 O
14 O
0 O
Nausea B-OSE_Labeled_AE
75 O
2 O
37 O
0 O
Vomiting B-OSE_Labeled_AE
32 O
4 O
9 O
0 O
Diarrhea B-OSE_Labeled_AE
28 O
4 O
21 O
2 O
Dyspepsia B-OSE_Labeled_AE
25 O
0 O
14 O
0 O
Dysgeusia B-OSE_Labeled_AE
21 O
0 O
9 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
( O
including O
asthenia B-OSE_Labeled_AE
, O
lethargy B-OSE_Labeled_AE
) O
68 O
6 O
53 O
2 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
/ O
Pharyngitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
43 O
0 O
16 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
/ O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
32 O
4 O
21 O
0 O
Myalgia B-OSE_Labeled_AE
25 O
2 O
12 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
25 O
6 O
21 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorder I-NonOSE_AE
Headache B-OSE_Labeled_AE
25 O
0 O
19 O
2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
Mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
21 O
0 O
14 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Dermatitis B-OSE_Labeled_AE
/ O
Rash B-OSE_Labeled_AE
25 O
0 O
14 O
0 O
Table O
4 O
Laboratory O
Abnormalities O
in O
Patients O
with O
gBRCA-Mutated O
Ovarian O
Cancer O
in O
the O
Randomized O
Trial O
Laboratory O
parameter1 O
Lynparza O
N=53 O
Placebo O
N=43 O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
85 O
8 O
58 O
2 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
32 O
8 O
23 O
0 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
26 O
6 O
19 O
0 O
Mean B-OSE_Labeled_AE
corpuscular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
85 O
- O
44 O
- O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
Patients O
were O
allowed O
to O
enter O
clinical O
studies O
with O
laboratory O
values O
of O
CTCAE O
Grade O
1 O
. O

26 O
0 O
5 O
0 O

